These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15510240)

  • 1. Memantine hydrochloride: pharmacological and clinical profile.
    Möbius HJ; Stöffler A; Graham SM
    Drugs Today (Barc); 2004 Aug; 40(8):685-95. PubMed ID: 15510240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of memantine for the treatment of Alzheimer's disease.
    Ferris SH
    Expert Opin Pharmacother; 2003 Dec; 4(12):2305-13. PubMed ID: 14640929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
    Olivares D; Deshpande VK; Shi Y; Lahiri DK; Greig NH; Rogers JT; Huang X
    Curr Alzheimer Res; 2012 Jul; 9(6):746-58. PubMed ID: 21875407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
    Lipton SA
    Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA
    Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Memantine: a review of its use in Alzheimer's disease.
    Robinson DM; Keating GM
    Drugs; 2006; 66(11):1515-34. PubMed ID: 16906789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memantine.
    Jarvis B; Figgitt DP
    Drugs Aging; 2003; 20(6):465-76; discussion 477-8. PubMed ID: 12710865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors.
    Gilling KE; Jatzke C; Hechenberger M; Parsons CG
    Neuropharmacology; 2009 Apr; 56(5):866-75. PubMed ID: 19371579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine. Merz.
    Kilpatrick GJ; Tilbrook GS
    Curr Opin Investig Drugs; 2002 May; 3(5):798-806. PubMed ID: 12090556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mémantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease].
    Gallarda T; Lôo H
    Encephale; 2004; 30(1):69-79. PubMed ID: 15029079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.
    Plosker GL; Lyseng-Williamson KA
    Pharmacoeconomics; 2005; 23(2):193-206. PubMed ID: 15748093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A; Alfaro V
    Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
    Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
    JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia.
    Koch HJ; Szecsey A; Haen E
    Curr Pharm Des; 2004; 10(3):253-9. PubMed ID: 14754385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of memantine in the treatment of dementia.
    Rossom R; Adityanjee ; Dysken M
    Am J Geriatr Pharmacother; 2004 Dec; 2(4):303-12. PubMed ID: 15903287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's disease and the glutamate NMDA receptor.
    Doraiswamy PM
    Psychopharmacol Bull; 2003; 37(2):41-9. PubMed ID: 14566213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine for dementia?
    Drug Ther Bull; 2003 Oct; 41(10):73-6. PubMed ID: 14593973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse.
    Parsons CG; Stöffler A; Danysz W
    Neuropharmacology; 2007 Nov; 53(6):699-723. PubMed ID: 17904591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.